Cariprazine (Vraylar)

Small molecule

Also known as MP-214

Approvedregulatory verdict

Evidence outlook

Approved: Major Depressive Disorder, Schizophrenia, Bipolar Disorder, Bipolar Depression

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
CA
  • Vraylar (Allergan Inc.): schizophrenia in adults; bipolar I disorder
Product first approved 2022dhpp.hpfb-dgpsa.ca
EU
  • Reagila (cariprazine, Gedeon Richter): schizophrenia in adult patients
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (22)
Bipolar Disorder
NCT04578756 · AbbVie
2021-02-01 – 2025-10-06 · Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
What this study did
NCT04771299 · Lakshmi N Yatham
2021-07-07 – 2024-09-08 · Bipolar I Disorder, Cognitive Impairment
What this study did
NCT03573297 · AbbVie
2018-06-15 – 2022-09-05 · Bipolar I Disorder, Mania, Depression
What this study did
NCT01059539 · Forest Laboratories
2010-02-28 – 2012-02-29 · Bipolar I Disorder
What this study did
Major Depressive Disorder
NCT01715805 · Forest Laboratories
2012-11-15 – 2016-06-24 · Major Depressive Disorder
What this study did
NCT01838876 · Forest Laboratories
2013-04-29 – 2015-07-27 · Major Depressive Disorder
What this study did
Schizophrenia
NCT03817502 · Gedeon Richter Plc.
2019-06-06 – 2026-12-15 · Schizophrenia
What this study did
NCT05368558 · AbbVie
2022-08-18 – 2024-09-20 · Schizophrenia
What this study did
NCT05168007 · Whanin Pharmaceutical Company
2021-11-19 – 2023-07-31 · Schizophrenia
What this study did
NCT01412060 · Forest Laboratories
2011-09-27 – 2014-09-03 · Schizophrenia
What this study did
NCT01104792 · Forest Laboratories
2010-05-31 – 2013-01-31 · Schizophrenia
What this study did
Other / comorbidity
Phase 2/3 (6)
Schizophrenia
NCT07722728 · Bostal Drug Delivery Co., Ltd
2026-08 – 2027-12 · Schizophrenia
What this study did
NCT01626872 · Tanabe Pharma Corporation
2012-09 – 2016-10 · Schizophrenia
What this study did
NCT01625000 · Tanabe Pharma Corporation
2012-05 – 2015-10 · Schizophrenia
What this study did
NCT01625897 · Tanabe Pharma Corporation
2012-05 – 2015-03 · Schizophrenia
What this study did
NCT01626885 · Tanabe Pharma Corporation
2012-05 – 2014-06 · Schizophrenia
What this study did
NCT01626859 · Tanabe Pharma Corporation
2012-05 – 2013-08 · Schizophrenia
What this study did
Phase 2 (12)
Bipolar Depression
NCT00852202 · Forest Laboratories
2009-06-30 – 2010-06-15 · Bipolar Depression
What this study did
Bipolar Disorder
Major Depressive Disorder
NCT01469377 · Forest Laboratories
2011-12-15 – 2013-12-12 · Major Depressive Disorder
What this study did
NCT00854100 · Forest Laboratories
2009-06-30 – 2010-12-06 · Major Depressive Disorder
What this study did
Schizophrenia
NCT00839852 · Forest Laboratories
2009-05-31 – 2010-08-31 · Schizophrenia
What this study did
NCT00862992 · Tanabe Pharma Corporation
2008-04 – 2009-09 · Schizophrenia
What this study did
NCT00694707 · Forest Laboratories
2008-06-30 – 2009-08-31 · Schizophrenia
What this study did
NCT00404573 · Forest Laboratories
2006-11 – 2007-08 · Schizophrenia
What this study did
Other / comorbidity
NCT05063201 · Kyle Kampman
2022-08-05 – 2025-12-31 · Opioid-use Disorder, Cocaine Use Disorder
What this study did
NCT03430544 · Anna Rose Childress, Ph.D.
2018-04-04 – 2020-09-04 · Cocaine Use Disorder
What this study did
Phase 1/2 (1)
Major Depressive Disorder
NCT07185815 · Mapi Pharma Ltd.
2025-08-01 – 2027-06-03 · Schizophrenia, Bipolar I Disorder, Major Depressive Disorder
What this study did
Phase 1 (6)
Schizophrenia
NCT07715253 · New York State Psychiatric Institute
2026-12-01 – 2030-11-30 · Schizoaffective Disorder, Schizophreniform Disorder, Schizophrenia
What this study did
NCT07691190 · Humanis Saglık Anonim Sirketi
2026-03-05 – 2026-06-26 · SCHIZOPHRENIA 1 (Disorder)
What this study did
NCT01376076 · Forest Laboratories
2011-06 – 2012-02 · Schizophrenia
What this study did
Other / comorbidity
NCT07121868 · Aya Mohammed Abdel Magid Abdel Hamid
2024-08-03 – 2025-01-23 · Bioequivalence Study in Healthy Subjects
What this study did
NCT04382885 · AbbVie
2020-06-26 – 2021-12-10 · Autism Spectrum Disorder
What this study did
NCT02165098 · Gedeon Richter Plc.
2014-06 – 2016-02 · Pharmacokinetic Profile
What this study did
Phase 4 (7)
Bipolar Depression
NCT07266545 · Mayo Clinic
2026-02-17 – 2030-12-31 · Unipolar Depression, Bipolar Depression
What this study did
NCT06433635 · Massachusetts General Hospital
2024-10-01 – 2030-02-28 · Bipolar I Disorder, Depression
What this study did
NCT05913947 · Aalborg University Hospital
2022-12-13 – 2028-09-02 · Depression, Bipolar
What this study did
NCT05060549 · New York State Psychiatric Institute
2026-01-06 – 2027-05-01 · Bipolar Depression
What this study did
Major Depressive Disorder
NCT05933538 · Sultan Qaboos University
2024-08 – 2030-12 · Depressive Disorder, Major
What this study did
Other / comorbidity
NCT05384483 · The Medical Research Network
2022-07-18 – 2024-04-15 · Social Anxiety Disorder
What this study did
NCT04843423 · Dr. Martin A. Katzman
2021-12-01 – 2023-04-14 · Attention Deficit Hyperactivity Disorder
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (2)
Bipolar Disorder
NCT07665073 · Pakistan Institute of Medical Sciences
2027-06 – 2028-06 · Bipolar 1 Disorder
What this study did
Other / comorbidity

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Depression: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Cariprazine (Vraylar): this drugApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptornot yet gradedNo reviewed efficacy summary in this indication
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
D-Cycloserine / Lurasidone (NRX-101)Phase 3Small moleculeNMDA receptor (glycine site) + dopamine/5-HT receptornot yet gradedNo reviewed efficacy summary in this indication
ABBV-932
Phase 1(overall)
Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Cariprazine (Vraylar) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3SchizophreniaRecruiting
Est. primary completion 2026-12-15 · NCT03817502 · CT.gov ↗
What to watch
Phase 1/2Major Depressive DisorderRecruiting
Est. primary completion 2026-12-31 · NCT07185815 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Phase 3Bipolar DisorderRecruiting
Est. primary completion 2027-03 · NCT04777357 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2/3SchizophreniaNot yet recruiting
Est. primary completion 2027-08 · NCT07722728 · CT.gov ↗
What to watch
2028 (2)
September 2028 (1)
Phase 4Bipolar DepressionRecruiting
Est. primary completion 2028-09-01 · NCT05913947 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Bipolar DepressionRecruiting
Est. primary completion 2028-12-31 · NCT07266545 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 4Bipolar DisorderActive not recruiting
Est. primary completion 2030-02-28 · NCT06433635 · CT.gov ↗
What to watch
August 2030 (2)
Phase 4Major Depressive DisorderNot yet recruiting
Est. primary completion 2030-08 · NCT05933538 · CT.gov ↗
What to watch
Phase 1SchizophreniaNot yet recruiting
Est. primary completion 2030-08-30 · NCT07715253 · CT.gov ↗
What to watch

See the full readout calendar ↗